Electronic Supplementary Material (ESI) for Organic & Biomolecular Chemistry. This journal is © The Royal Society of Chemistry 2018

Supporting Information for

5'- Vitamin B_{12} derivatives suitable for bioconjugation via the amide bond


Agnieszka Jackowska, a Mikolaj Chromiński, a Maciej Giedyka* and Dorota Grykoa*

^aInstitute of Organic Chemistry Polish Academy of Sciences, Kasprzaka 44/52, 01-224 Warsaw

Table of contents

1.	Optimization of the synthesis of amide 7b with coupling reagent
2.	Optimization of the synthesis of acid 8
3.	Optimization of the synthesis of amide 11a via active ester step
4.	HPLC chromatograms4
5.	¹ H NMR (500 MHz) and ¹³ C NMR (126 MHz) of compound 5 in CD ₃ OD
6.	¹ H NMR (500 MHz) and ¹³ C NMR (126 MHz) of compound 7a in CD ₃ OD
7.	¹ H NMR (500 MHz) and ¹³ C NMR (126 MHz) of compound 7b in CD ₃ OD
8.	¹ H NMR (500 MHz) and ¹³ C NMR (126 MHz) of compound 7c in CD ₃ OD
9.	¹ H NMR (500 MHz) and ¹³ C NMR (126 MHz) of compound 7a (in physiological conditions)
	in CD ₃ OD
10.	¹ H NMR (500 MHz) and ¹³ C NMR (126 MHz) of compound 7b (with coupling reagent)
	in CD ₃ OD
11.	¹ H NMR (500 MHz) and ¹³ C NMR (126 MHz) of compound 7d (with coupling reagent)
	in CD ₃ OD
12.	¹ H NMR (500 MHz) and ¹³ C NMR (126 MHz) of compound 8 in CD ₃ OD
13.	¹ H NMR (500 MHz) and ¹³ C NMR (126 MHz) of compound 11a (via active ester step)
	in CD ₃ OD
14.	¹ H NMR (500 MHz) and ¹³ C NMR (126 MHz) of compound 11a in CD ₃ OD
15.	¹ H NMR (500 MHz) and ¹³ C NMR (126 MHz) of compound 11b in CD ₃ OD
16.	¹ H NMR (500 MHz) and ¹³ C NMR (126 MHz) of compound 11c in CD ₃ OD

1. Optimization of the synthesis of amide **7b** with coupling reagent^a



Entry	Coupling agent	Solvents	Base	Yield [%] ^b
1	DCC	DMF/H ₂ O (1:1)	DIPEA	14
2	EDC	DMF/H ₂ O (1:1)	DIPEA	0
3	HBTU, HOBt	DMF/H ₂ O (1:1)	DIPEA	26
4	HBTU, HOBt	DMSO/H ₂ O (1:1)	DIPEA	31
5	HBTU, HOBt	DMF/H ₂ O/dioxane (2:1:2)	DIPEA	57
6	HBTU, HOBt	DMSO/H ₂ O/dioxane (2:1:2)	DIPEA	70
7	HBTU, HOBt	DMF/H ₂ O/DMSO (2:1:2)	DIPEA	82
8	HBTU, HOBt	DMF/H ₂ O/DMSO (2:1:2)	DMAP	85
9	HBTU, HOBt	DMF/H ₂ O/DMSO (2:1:2)	Et ₃ N	70
10 ^c	HBTU, HOBt	DMF/H ₂ O/DMSO (2:1:2)	DMAP	88

^aGeneral conditions: amine **5** (15 mg, 10 μmol), *N*-Boc-Gly-OH (9 mg, 51 μmol), DCC (11 mg, 51 μmol), EDC (10 mg, 51 μmol), HBTU (19 mg, 51 μmol), HOBt (7 mg, 51 μmol), DIPEA (9 μL, 51 μmol), DMAP (6 mg, 51 μmol), Et₃N (7 μL, 51 μmol), total volume of solvents was 1.5 mL (v/v/v), r.t., 4 h; ^bIsolated yield; ^cReaction performed with 102 μmol of *N*-Boc-Gly-OH, HBTU, HOBt and DMAP.


2. Optimization of the synthesis of acid 8^a



Entry	Succinic anhydride [equiv.]	Pyridine [equiv.]	Temperature [°C]	Time [h]	Yield [%] ^b
1	5	5	r.t.	5	67
2	5	5	r.t.	17	91
3	10	10	r.t.	5	87
4	10	10	r.t.	17	96
5	5	5	40	5	81
6	5	5	40	17	96
7	10	10	40	5	96
8	10	10	40	17	96

^aGeneral conditions: amine **5** (5 mg, 3 μmol), DMSO (5 mL); ^bYield estimated based on HPLC analysis.

3. Optimization of the synthesis of amide 11a via active ester step^a




Entry	TSTU [equiv.]	DIPEA [equiv.]	Solvents	Yield [%] ^b
1	2.0	2.0	DMF/H ₂ O/dioxane (2:1:2)	16
2	4.0	4.0	DMF/H ₂ O/dioxane (2:1:2)	30
3	8.0	8.0	DMF/H ₂ O/dioxane (2:1:2)	54
4	20.0	20.0	DMF/H ₂ O/dioxane (2:1:2)	traces
5	8.0	8.0	DMF/H ₂ O (2:1)	43
6	8.0	8.0	DMF/0.1 M NaHCO ₃ /dioxane (2:1:2)	15
7^c	8.0	8.0	DMF/0.1 M NaHCO ₃ /dioxane (2:1:2)	9
8	8.0	8.0	MeCN/H ₂ O/dioxane (2:1:2)	41
9	8.0	8.0	NMP/H ₂ O/dioxane (2:1:2)	22


^aGeneral conditions: acid **8** (15 mg, 10 μmol), total volume of solvents was 1.5 mL (v/v/v), r.t., 20 h, amine **10a** (4.0 μL, 20 μmol), r.t., 75 min; ^bIsolated yield; ^cWithout DIPEA.


4. HPLC chromatograms

HPLC Method


Time [min]	H ₂ O + 0.5% TFA [%]	MeCN [%]	λ [nm]	
Initial	90	10	261	
15	30	70	361	










5. ¹H NMR (500 MHz) and ¹³C NMR (126 MHz) of compound **5** in CD₃OD (for clarity only well isolated signals are integrated)







6. ¹H NMR (500 MHz) and ¹³C NMR (126 MHz) of compound **7a** in CD₃OD (for clarity only well isolated signals are integrated)







7. ¹H NMR (500 MHz) and ¹³C NMR (126 MHz) of compound **7b** in CD₃OD (for clarity only well isolated signals are integrated)







8. ¹H NMR (500 MHz) and ¹³C NMR (126 MHz) of compound **7c** in CD₃OD (for clarity only well isolated signals are integrated)







9. ¹H NMR (500 MHz) and ¹³C NMR (126 MHz) of compound **7a** (in physiological conditions) in CD₃OD (for clarity only well isolated signals are integrated)







10. ¹H NMR (500 MHz) and ¹³C NMR (126 MHz) of compound **7b** (with coupling reagent) in CD₃OD (for clarity only well isolated signals are integrated)







11. ¹H NMR (500 MHz) and ¹³C NMR (126 MHz) of compound **7d** (with coupling reagent) in CD₃OD (for clarity only well isolated signals are integrated)







12. ¹H NMR (500 MHz) and ¹³C NMR (126 MHz) of compound **8** in CD₃OD (for clarity only well isolated signals are integrated)







13. ¹H NMR (500 MHz) and ¹³C NMR (126 MHz) of compound **11a** (via active ester step) in CD₃OD (for clarity only well isolated signals are integrated)







14. ¹H NMR (500 MHz) and ¹³C NMR (126 MHz) of compound **11a** in CD₃OD (for clarity only well isolated signals are integrated)





15. ¹H NMR (500 MHz) and ¹³C NMR (126 MHz) of compound **11b** in CD₃OD (for clarity only well isolated signals are integrated)





16. ¹H NMR (500 MHz) and ¹³C NMR (126 MHz) of compound **11c** in CD₃OD (for clarity only well isolated signals are integrated)

